Alcoholic cardiomyopathy: aspects of pathogenesis and clinic

Alcoholic cardiomyopathy is the most common form of myocardial damage caused by ethanol. Ethanol and its main active metabolite acetaldehyde have a direct toxic effect on the myocardium. The mechanisms of the cardiotoxic effect of ethanol are diverse and include membranotropic action, damage to cellular organelles, activation of lipid peroxidation, and a number of others. Dissolving in the lipids of biological membranes, ethanol changes their physico-chemical properties, disrupts the activity of membrane receptors, eventually disconnecting the connection of excitation with the contraction of cardiomyocytes. Particular importance in the pathogenesis of alcoholic cardiomyopathy is attached to the ability of ethanol to cause structural and functional changes in mitochondria, which is directly related to the violation of oxidative processes and energy supply of the myocardium as a whole. Under the influence of alcohol, free-radical lipid oxidation products content increases and antioxidants activity decreases, which indicates oxidative stress development. The deterioration of myocardial contractility due to chronic alcohol intoxication triggers a cascade of compensatory mechanisms in the form of cardiomyocyte hypertrophy and progressive fibrosis, while adaptive reactions become a factor in further pathological changes. Ethanol causes myocardial damage in a dose-dependent manner.

The probability of alcoholic cardiomyopathy occurrence is a derivative of the total accumulated dose of alcohol and individual predisposition. Alcoholic cardiomyopathy is considered as a variant of secondary dilated cardiomyopathy with all its clinical manifestations and consequences: dilation of the heart chambers, low left ventricular ejection fraction, progressive circulatory insufficiency, and cardiac arrhythmias. A relatively favorable prognosis in alcoholic cardiomyopathy is provided due to partial reversibility of myocardial damage under the condition of abstinence from alcohol consumption. Specific drugs for the treatment of alcoholic cardiomyopathy have not been developed. New treatment strategies include the use of myocardial growth and regulation factors synthesized by cardiomyocytes, as well as the stimulation of heart muscle regeneration and repair processes.

1. Kobalava Zh.D., Lazarev P.V., Goncharov A.S. A modern view on the pathogenesis, diagnosis and treatment of alcoholic cardiomyopathy. Rossijskij kardiologicheskij zhurnal = Russian Journal of Cardiology 2019;24(11):164–72. (In Russ.). DOI: 10.15829/1560-4071-2019-11-164–172

2. Raikhelson K.L., Kondrashina E.A., Pazenko E.V. Principles of treatment of different forms of alcoholic liver disease: A review. Terapevticheskiy arkhiv = Therapeutic Archive 2023;95(2):187–92. (In Russ.). DOI: 10.26442/00403660.2023.02.202071

3. Testino G., Pellicano R., Caputo F. Alcohol consumption, alcohol use disorder and organ transplantation. Minerva Gastroenterol (Torino) 2023;69(4):553–65. DOI: 10.23736/S2724-5985.22.03281-8

4. Levesque C., Sanger N., Edalati H. et al. A systematic review of relative risks for the relationship between chronic alcohol use and the occurrence of disease. Alcohol Clin Exp Res 2023;47(7):1238–55. DOI: 10.1111/acer.15121

5. Fadeev G.A., Tsybulkin N.A., Mikhoparova O.Y., Tukhvatullina G.V. Pathogenetic mechanisms of alcoholic cardiomyopathy development. Vestnik sovremennoj klinicheskoj mediciny =The Bulletin of Contemporary Clinical Medicine 2019;12(4):74–80. (In Russ.). DOI: 10.20969/VSKM.2019.12(4).74-80

6. Fatjó F., Sancho-Bru P., Fernández-Solà J. et al. Up-regulation of myocardial L-type Ca2+ channel in chronic alcoholic subjects without cardiomyopathy. Alcohol Clin Exp Res 2007;31(7):1099–105. DOI: 10.1111/j.1530-0277.2007.00404.x

7. Fernández-Solà J. The effects of ethanol on the heart: alcoholic cardiomyopathy. Nutrients 2020;12(2):572. DOI: 10.3390/nu12020572

8. Thomas A.P., Corrêa-Velloso J.C. Calcium wave propagation underlying intercellular signaling and coordination of tissue responses. Function 2022;3(2):1–3. DOI: 10.1093/function/zqac011

9. Molina P.E., Gardner J.D., Souza-Smith F.M., Whitaker A.M. Alcohol abuse: Critical pathophysiological processes and contribution to disease burden. Physiology (Bethesda) 2014;29(3):203–15. DOI:10.1152/physiol.00055.2013

10. Piano M.R., Phillips S.A. Alcoholic cardiomyopathy: Pathophysiologic insights. Cardiovasc Toxicol 2014;14(4):291–308. DOI: 10.1007/s12012-014-9252-4

11. Dinis-Oliveira R.J. Oxidative and non-oxidative metabolomics of ethanol. Curr Drug Metab 2016;17(4):327–35. DOI: 10.2174/1389200217666160125113806

12. Steiner J.L., Lang C.H. Etiology of alcoholic cardiomyopathy: Mitochondria, oxidative stress and apoptosis. Int J Biochem Cell Biol 2017;89:125–35. DOI: 10.1016/j.biocel.2017.06.009

13. Matyas C., Varga Z.V., Mukhopadhyay P. et al. Chronic plus binge ethanol feeding induces myocardial oxidative stress, mitochondrial and cardiovascular dysfunction, and steatosis. Am J Physiol Heart Circ Physiol 2016;310(11):1658–70. DOI: 10.1152/ajpheart.00214.2016

14. Liu S.M., Zhao Q., Li W.J., Zhao J.Q. Advances in the study of MG53 in cardiovascular disease. Int J Gen Med 2023;16:6073–82. DOI: 10.2147/IJGM.S435030

15. Li A., Shami G.J., Griffiths L. et al. Giant mitochondria in cardiom yocytes: cellular architecture in health and disease. Basic Res Cardiol 2023;118(1):39. DOI: 10.1007/s00395-023-01011-3

16. Roerecke M. Alcohol’s impact on the cardiovascular system. Nutrients 2021;13(10):3419. DOI: 10.3390/nu13103419

17. Xiong J., Cao X., Qiao S. et al. (Pro)renin receptor is involved in myocardial damage in alcoholic cardiomyopathy. Alcohol Clin Exp Res 2019;43(11):2344–53. DOI: 10.1111/acer.141882019

18. Ma X., Liao Z., Li R. et al. Myocardial injury caused by chronic alcohol exposure – a pilot study based on proteomics. Molecules 2022;27(13):4284. DOI: 10.3390/molecules27134284

19. Li X., Nie Y., Lian H., Hu S. Histopathologic features of alcoholic cardiomyopathy compared with idiopathic dilated cardiomyopathy. Go Med 2018;97(39):e12259. DOI:10.1097/MD.0000000000012259.

20. Day E., Rudd J.H.F. Alcohol use disorders and the heart. Addiction 2019;114(9):1670–8. DOI: 10.1111/add.14703

21. Mirijello A., Tarli C., Vassallo G.A. et al. Alcoholic cardiomyopathy: what is known and what is not known. Eur J Intern Med 2017;43:1–5. DOI: 10.1016/j.ejim.2017.06.014

22. Okeyo I., Walmisley U., De Jong M. et al. Whole-of-community interventions that address alcohol-related harms: protocol for a scoping review. BMJ Open 2022;12(7):e059332. DOI: 10.1136/bmjopen-2021-059332

23. Tayal U., Gregson J., Buchan R. et al. Moderate excess alcohol consumption and adverse cardiac remodelling in dilated cardiomyopathy. Heart 2022;108(8):619–25. DOI: 10.1136/heartjnl-2021-319418

24. Wu L., Zhang Y., Ren J. Epigenetic modification in alcohol use disorder and alcoholic cardiomyopathy: from pathophysiology to therapeutic opportunities. Metabolism 2021:125:154909. DOI: 10.1016/j.metabol.2021.154909

25. Fernández-Solà J. Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol 2015;12(10):576–87. DOI:10.1038/nrcardio.2015.91

26. Shaaban A., Gangwani M.K., Pendela V.S., Vindhyal M.R. Alcoholic Cardiomyopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. PMID: 30020694

27. O’Keefe J.H., Bhatti S.K., Bajwa A. et al. Alcohol and cardiovascular health: The dose makes the poison... or the remedy. Mayo Clin Proc 2014;89(3):382–93. DOI: 10.1016/j.mayocp.2013.11.005

28. Rehm J., Hasan O.S.M., Imtiaz S., Neufeld M. Quantifying the contribution of alcohol to cardiomyopathy: A systematic review. Alcohol 2017;61:9–15. DOI: 10.1016/j.alcohol.2017.01.011

29. Maisch B. Alcoholic cardiomyopathy: Alcoholic cardiomyopathy. The result of dosage and individual predisposition. Herz 2016;41(6):484–93. DOI: 10.1007/s00059-016-4469-6

30. Gál R., Halmosi R., Gallyas F.Jr. et al. Resveratrol and beyond: The effect of natural polyphenols on the cardiovascular system: A narrative review. Czopf L Biomedicines 2023;11(11):2888. DOI: 10.3390/biomedicines11112888

31. Płachta Ł., Mach M., Kowalska M., Wydro P. The effect of trans- resveratrol on the physicochemical properties of lipid membranes with different cholesterol content. Biochim Biophys Acta Biomembr 2024;1866(1):184212. DOI: 10.1016/j.bbamem.2023.184212

32. Wong C.X., Tu S.J., Marcus G.M. Alcohol and arrhythmias. JACC Clin Electrophysiol 2023;9(2):26–79. DOI: 10.1016/j.jacep.2022.10.023

33. Lucerón-Lucas-Torres M., Saz-Lara A., Díez-Fernández A. et al. Association between wine consumption with cardiovascular disease and cardiovascular mortality: a systematic review and meta-analysis. Nutrients 2023;15(12):2785. DOI: 10.3390/nu15122785

34. Muraki I., Iso H., Imano H. et al. Alcohol Consumption and long- term mortality in men with or without a history of myocardial infarction. Atheroscler Thromb 2023;30(4):415–28. DOI: 10.5551/jat.63517

35. van der Heide F.C.T., Eussen S.J.P.M., Houben A.J.H.M. et al. Alcohol consumption and microvascular dysfunction: a J-shaped association: The Maastricht Study. Cardiovasc Diabetol 2023;22(1):67. DOI: 10.1186/s12933-023-01783-x

36. Ma J., Huang A., Yan K. et al. Hum Blood transcriptomic biomarkers of alcohol consumption and cardiovascular disease risk factors: The Framingham Heart Study. Mol Genet 2023;32(4): 649–58. DOI: 10.1093/hmg/ddac237

37. Andersson C., Schou M., Gustafsson F., Torp-Pedersen C. Alcohol intake in patients with cardiomyopathy and heart failure: consensus and controversy. Circ Heart Fail 2022;15(8):e009459. DOI: 10.1161/CIRCHEARTFAILURE.121.009459

38. Pfeiffer D., Jurisch D., Neef M., Hagendorff A. Alcohol and arrhythmias. Herz 2016;41(6):498–502. DOI: 10.1007/s00059-016-4463-z

39. Fang W., Luo R., Tang Y. et al. The prognostic factors of alcoholic cardiomyopathy: a single-center cohort study. Medicine 2018;97(31):e11744. DOI: 10.1097/MD.0000000000011744

40. Dundung A., Kumar A., Guria R.T. et al. Clinical profile and prognostic factors of alcoholic cardiomyopathy in tribal and non-tribal population. Open Heart 2020;7(2):e001335. DOI: 10.1136/openhrt-2020-001335

41. Ram P., Lo K.B., Shah M. et al. National trends in hospitalizations and outcomes in patients with alcoholic cardiomyopathy. Clin Cardiol 2018;41(11):1423–9. DOI: 10.1002/clc.23067

42. Lee J.W., Roh S.Y., Yoon W.S et al. Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. Eur J Prev Cardiol 2024;31(1):49–58. DOI: 10.1093/eurjpc/zwad270

43. Edavettal J.M., Harris N.R., Cohen S.E. et al. Abstinence restores cardiac function in mice with established alcohol-induced cardiomyopathy. Cells 2023;12(24):2783. DOI: 10.3390/cells12242783

44. Glymour M.M. Alcohol and cardiovascular disease. BMJ 2014;349:g4334. DOI: 10.1136/bmj.g4334